For Biotech Startups

It's 10 years between Phase 1b and market. We make it 10 months.

Regulatory. Manufacturing. Clinic operations. Patient delivery. Meet your Japanese deployment partner.

Talk to us

The right moment

Why Japan?

We use Japan's novel regulatory pathways to help you deploy into market years before FDA approval.

  • 01

    One of the world’s biggest consumer markets.

    Japan is a massive market, and right now with a weak yen it is easier than ever to enter.

  • 02

    Early commercialization is a value inflection.

    Being able to commercialize early helps you raise the capital needed for further clinical studies.

  • 03

    Faster path to the FDA.

    Therapies deployed in Japan get green-lit by the FDA faster. Our post-marketing data collection helps you secure regulatory approvals elsewhere.

All you need is Phase 1b data from a trustworthy CRO. Earlier than that? Join one of our residencies to figure out how to do first-in-human in Japan. Click here for more information.

Why us

One point of contact.

End-to-end support.

We offer you and your future patients end-to-end support — we are a partner that runs the protocol from first consult to long-term monitoring.

  1. 00 Regulatory approval secured through one of our deployment partners.
  2. 01 Commercial launch across our network of partner clinics.
  3. 02 Clinical coordination between physicians, laboratories, and patients.
  4. 03 Manufacturing oversight from sample to finished dose.
  5. 04 Medical tourism logistics for international patients.
  6. 05 Long-term patient follow-up and anonymized data collection.

Proof

Big Pharma has already pushed 20+ therapies into the market using these pathways. We're making it accessible for startups.

SNK01  ·  Preparing for launch

Q3 '26 widely available.

A therapy that received approval on a promising ten-patient study. No adverse side effects across dosages.

05 / Begin

Let's talk.

Start a conversation